undamentalytics Newsletter

Gepsman Martin J: insider trades

Director at CME Group. No open-market purchases and 31 sales not made under a pre-set plan, reported from May 7, 2013 to October 22, 2026.

What happened after Gepsman Martin J’s sales?

After their sales, the shares moved +3.4% against the index over 12 months on average (a negative figure means selling was the right call); 31% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

Gepsman Martin J: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 30 +4.6% +7.5% 30% 13 0.53 0.60 No reliable evidence
Sales, 12 months after the report 29 +3.4% +6.0% 31% 12 0.48 0.64 No reliable evidence
Sales, 12 months after the trade 29 +3.5% +5.0% 31% 12 0.52 0.61 No reliable evidence

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
CME Group CME —031May 7, 2013October 22, 2026

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
October 22, 2026October 22, 2026 CME Sale $121,000 not yetnot yetnot yet
February 20, 2026February 20, 2026 CME Sale $91,770 −14.6%not yetnot yet
May 19, 2025May 15, 2025 CME Sale $81,951 −8.7%−18.6%−10.9%
November 4, 2024November 4, 2024 CME Sale $89,168 +7.4%+10.5%+8.0%
October 26, 2023October 26, 2023 CME Sale $64,899 −18.4%−29.8%−31.8%
December 9, 2021December 7, 2021 CME Sale $115,500 +13.5%−4.1%−6.6%
October 28, 2021October 28, 2021 CME Sale $109,133 +7.7%−4.2%−3.5%
September 13, 2021September 13, 2021 CME Sale $188,540 +15.8%+14.6%+16.7%
September 8, 2021September 7, 2021 CME Sale $194,250 +15.6%+16.2%+17.4%
August 30, 2021August 30, 2021 CME Sale $201,003 +8.6%+11.4%+11.9%
August 23, 2021August 23, 2021 CME Sale $201,370 +7.7%+8.8%+7.7%
March 12, 2021March 11, 2021 CME Sale $308,190 −3.6%+6.7%+4.9%
December 15, 2020December 14, 2020 CME Sale $71,376 +7.6%+2.2%+3.3%
December 2, 2020December 1, 2020 CME Sale $142,880 +15.5%+2.6%+1.9%
September 3, 2020September 2, 2020 CME Sale $867,600 +0.7%−15.8%−10.4%
January 7, 2020January 3, 2020 CME Sale $201,160 +3.2%−19.4%−26.0%
June 10, 2019June 6, 2019 CME Sale $503,025 0.0%−15.1%−16.2%
May 9, 2019May 7, 2019 CME Sale $356,140 +16.6%−0.2%−0.5%
March 18, 2019March 14, 2019 CME Sale $503,730 +12.9%+0.8%+13.4%
September 14, 2018September 13, 2018 CME Sale $51,689 +19.7%+22.8%+17.9%
May 29, 2018May 25, 2018 CME Sale $95,862 −3.9%+16.2%+18.3%
February 16, 2018February 15, 2018 CME Sale $49,287 −1.9%+6.7%+4.6%
August 11, 2017August 9, 2017 CME Sale $25,228 +6.0%+21.7%+17.2%
September 2, 2016September 2, 2016 CME Sale $32,700 +8.7%+10.2%+6.4%
August 2, 2016July 29, 2016 CME Sale $51,300 −1.1%+10.5%+10.0%
August 14, 2015August 12, 2015 CME Sale $67,850 +1.0%+6.0%+5.5%
March 5, 2015March 3, 2015 CME Sale $48,325 −1.0%+4.1%+5.0%
November 17, 2014November 14, 2014 CME Sale $42,390 +12.4%+16.3%+15.2%
August 1, 2014August 1, 2014 CME Sale $59,568 +9.2%+26.1%+25.4%
November 20, 2013November 18, 2013 CME Sale $39,770 −12.3%−11.8%−5.7%
May 7, 2013May 6, 2013 CME Sale $30,520 +15.1%+3.3%+1.2%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Gepsman Martin J traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.